Floatz logo

Lornoxicam

Effects of Chemotherapy

Shi YanxiaSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

928 Active assets in the Effects of Chemotherapy cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Lornoxicam is also rated in:

triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
57 / 100
View asset →
migraine disorderDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →